EA038146B1 - Антитела к про-/латентному миостатину и их применения - Google Patents
Антитела к про-/латентному миостатину и их применения Download PDFInfo
- Publication number
- EA038146B1 EA038146B1 EA201890712A EA201890712A EA038146B1 EA 038146 B1 EA038146 B1 EA 038146B1 EA 201890712 A EA201890712 A EA 201890712A EA 201890712 A EA201890712 A EA 201890712A EA 038146 B1 EA038146 B1 EA 038146B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- seq
- pro
- antigen
- myostatin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219094P | 2015-09-15 | 2015-09-15 | |
| PCT/US2016/052014 WO2017049011A1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201890712A1 EA201890712A1 (ru) | 2018-09-28 |
| EA038146B1 true EA038146B1 (ru) | 2021-07-13 |
Family
ID=57043000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890712A EA038146B1 (ru) | 2015-09-15 | 2016-09-15 | Антитела к про-/латентному миостатину и их применения |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10751413B2 (enExample) |
| EP (3) | EP3922645B1 (enExample) |
| JP (4) | JP7107836B2 (enExample) |
| KR (3) | KR102596852B1 (enExample) |
| CN (5) | CN108350067B (enExample) |
| AU (2) | AU2016323447B2 (enExample) |
| BR (1) | BR112018004981A2 (enExample) |
| CA (1) | CA3036652A1 (enExample) |
| CO (1) | CO2018002703A2 (enExample) |
| CY (1) | CY1124619T1 (enExample) |
| DK (2) | DK3922645T3 (enExample) |
| EA (1) | EA038146B1 (enExample) |
| ES (2) | ES3030258T3 (enExample) |
| FI (1) | FI3922645T3 (enExample) |
| HR (2) | HRP20250666T1 (enExample) |
| HU (2) | HUE072064T2 (enExample) |
| IL (2) | IL305148A (enExample) |
| LT (2) | LT3350220T (enExample) |
| MX (5) | MX2018003196A (enExample) |
| PL (2) | PL3922645T3 (enExample) |
| PT (2) | PT3922645T (enExample) |
| RS (2) | RS66913B1 (enExample) |
| SI (2) | SI3350220T1 (enExample) |
| SM (2) | SMT202500263T1 (enExample) |
| WO (1) | WO2017049011A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| CA2865158C (en) | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| PL4218804T3 (pl) | 2016-06-13 | 2026-05-25 | Scholar Rock, Inc. | Stosowanie inhibitorów miostatyny i terapii skojarzonych |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| WO2018129395A1 (en) * | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| HRP20230308T1 (hr) * | 2017-01-06 | 2023-05-12 | Scholar Rock, Inc. | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina |
| PT3677278T (pt) | 2018-07-11 | 2022-02-03 | Scholar Rock Inc | Inibidores seletivos da isoforma tgfbeta1 e sua utilização |
| KR102891320B1 (ko) | 2018-07-11 | 2025-11-28 | 스칼러 락, 인크. | 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도 |
| SG11202108099WA (en) * | 2019-01-30 | 2021-08-30 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
| CN110429214B (zh) | 2019-08-07 | 2021-12-07 | 宁德时代新能源科技股份有限公司 | 二次电池的盖组件及二次电池 |
| CN120022360A (zh) * | 2019-08-28 | 2025-05-23 | 中外制药株式会社 | 跨物种抗潜伏TGF-β1抗体和使用方法 |
| CA3166328A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| RU2750267C1 (ru) * | 2020-02-07 | 2021-06-25 | Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» | Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата |
| EP4232151B1 (en) | 2020-10-26 | 2025-10-22 | Scholar Rock, Inc. | Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| DK4358995T3 (da) | 2021-06-23 | 2026-02-02 | Scholar Rock Inc | Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser |
| KR102840816B1 (ko) * | 2021-11-25 | 2025-07-31 | (주)네오크레마 | 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도 |
| KR102836354B1 (ko) * | 2021-11-25 | 2025-07-22 | (주)네오크레마 | 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도 |
| LT4518970T (lt) | 2022-05-04 | 2026-04-27 | Scholar Rock, Inc. | Miostatino inhibitoriaus panaudojimas spinalinės raumenų atrofijos gydymui |
| JP2025534681A (ja) | 2022-10-14 | 2025-10-17 | ジェネンテック， インコーポレイテッド | 脊髄性筋萎縮症の治療方法 |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
| EP4676954A1 (en) | 2023-03-07 | 2026-01-14 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
| WO2026076383A1 (en) | 2024-10-06 | 2026-04-09 | Scholar Rock, Inc. | Use of myostatin inhibitor for treating spinal muscular atrophy |
| WO2026147753A1 (en) | 2024-12-30 | 2026-07-09 | Scholar Rock, Inc. | Therapies for muscular dystrophies |
| EP4763222A1 (en) * | 2025-08-25 | 2026-06-24 | Qilu Pharmaceutical Co., Ltd. | A composition comprising apitegromab |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003027248A2 (en) * | 2001-09-26 | 2003-04-03 | Wyeth | Antibody inhibitors of gdf-8 and uses thereof |
| WO2004037861A2 (en) * | 2002-10-22 | 2004-05-06 | Wyeth | Neutralizing antibodies against gdf-8 and uses therefor |
| WO2005066204A2 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| WO2006116269A2 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Inc. | Antibodies to myostatin |
| US20130209489A1 (en) * | 2010-08-16 | 2013-08-15 | Huiquan Han | Antibodies That Bind Myostatin, Compositions And Methods |
| WO2014182676A2 (en) * | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| WO2016073853A1 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016098357A1 (en) * | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM. |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US7566768B1 (en) * | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| WO1995007994A2 (en) | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| HUT75162A (en) | 1993-11-16 | 1997-04-28 | Depotech Corp | Vesicles with controlled release of actives |
| DE69535669T2 (de) | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| DE69534468T2 (de) | 1994-07-08 | 2006-07-13 | The Johns Hopkins University School Of Medicine | Wachstums-differenzierungsfaktor-11 |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| PL357017A1 (en) | 2000-01-28 | 2004-07-12 | Novo Nordisk A/S | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| ATE364632T1 (de) | 2001-10-05 | 2007-07-15 | Affimed Therapeutics Ag | Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| US20040131614A1 (en) | 2002-07-19 | 2004-07-08 | Abbott Biotechnology Ltd. | Treatment of pulmonary disorders using TNFalpha inhibitor |
| AU2003267246A1 (en) | 2002-09-16 | 2004-04-30 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| AU2003301195B2 (en) | 2002-12-20 | 2010-01-07 | Amgen Inc. | Binding agents which inhibit myostatin |
| CA2558478A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| US20070178095A1 (en) | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EP1755648A2 (en) | 2004-05-27 | 2007-02-28 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| EP2361933A3 (en) | 2005-01-26 | 2012-05-02 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| US7888486B2 (en) * | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| KR101135220B1 (ko) | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| KR20070105685A (ko) | 2006-04-27 | 2007-10-31 | 영남대학교 산학협력단 | 메트포르민을 포함하는 비만치료용 조성물 |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| BRPI0715072A2 (pt) | 2006-08-03 | 2013-06-25 | Orico Ltd | antagonistas de miostatina |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| HRP20130320T1 (en) | 2006-09-05 | 2013-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
| WO2008067480A2 (en) | 2006-11-29 | 2008-06-05 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| KR101531722B1 (ko) | 2007-03-30 | 2015-06-25 | 메르크 파텐트 게엠베하 | 음성 광학 분산도를 갖는 복굴절층 |
| AU2008260445A1 (en) | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| TW201029662A (en) | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| JP2012520887A (ja) | 2009-03-18 | 2012-09-10 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物 |
| ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| US8945511B2 (en) | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
| NZ599604A (en) | 2009-10-01 | 2014-07-25 | Myostin Therapeutics Pty Ltd | Synthetic myostatin peptide antagonists |
| EP3904391B1 (en) | 2010-03-10 | 2024-07-10 | Genmab A/S | Monoclonal antibodies against c-met |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| AR081556A1 (es) * | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
| US8551892B2 (en) | 2011-07-27 | 2013-10-08 | Asm Japan K.K. | Method for reducing dielectric constant of film using direct plasma of hydrogen |
| WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| US20150284455A1 (en) | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| BR112015027336A2 (pt) | 2013-05-01 | 2017-09-26 | Genzyme Corp | composições e processos para tratamento de atrofia muscular espinhal |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| US10004814B2 (en) | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| EA201891420A1 (ru) | 2015-12-18 | 2019-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| PL4218804T3 (pl) | 2016-06-13 | 2026-05-25 | Scholar Rock, Inc. | Stosowanie inhibitorów miostatyny i terapii skojarzonych |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| WO2018129395A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| HRP20230308T1 (hr) | 2017-01-06 | 2023-05-12 | Scholar Rock, Inc. | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina |
| US20210087250A1 (en) | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| SG11202108099WA (en) | 2019-01-30 | 2021-08-30 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
| EP4232151B1 (en) | 2020-10-26 | 2025-10-22 | Scholar Rock, Inc. | Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy |
| CN117545842A (zh) | 2021-01-29 | 2024-02-09 | 拜奥卡德联合股份公司 | SMN1和miR-23a在治疗脊髓性肌萎缩中的协同效应 |
| DK4358995T3 (da) | 2021-06-23 | 2026-02-02 | Scholar Rock Inc | Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser |
| LT4518970T (lt) | 2022-05-04 | 2026-04-27 | Scholar Rock, Inc. | Miostatino inhibitoriaus panaudojimas spinalinės raumenų atrofijos gydymui |
| JP2025532651A (ja) | 2022-09-21 | 2025-10-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 肥満、糖尿病および肝機能障害を処置する方法 |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
-
2016
- 2016-09-15 EA EA201890712A patent/EA038146B1/ru unknown
- 2016-09-15 SI SI201631287T patent/SI3350220T1/sl unknown
- 2016-09-15 IL IL305148A patent/IL305148A/en unknown
- 2016-09-15 US US15/760,393 patent/US10751413B2/en active Active
- 2016-09-15 CN CN201680065184.7A patent/CN108350067B/zh active Active
- 2016-09-15 LT LTEP16774748.4T patent/LT3350220T/lt unknown
- 2016-09-15 HR HRP20250666TT patent/HRP20250666T1/hr unknown
- 2016-09-15 CN CN202111206744.5A patent/CN113896789B/zh active Active
- 2016-09-15 EP EP21170667.6A patent/EP3922645B1/en active Active
- 2016-09-15 SM SM20250263T patent/SMT202500263T1/it unknown
- 2016-09-15 FI FIEP21170667.6T patent/FI3922645T3/fi active
- 2016-09-15 JP JP2018513591A patent/JP7107836B2/ja active Active
- 2016-09-15 KR KR1020187010090A patent/KR102596852B1/ko active Active
- 2016-09-15 IL IL258121A patent/IL258121B2/en unknown
- 2016-09-15 MX MX2018003196A patent/MX2018003196A/es unknown
- 2016-09-15 SM SM20210432T patent/SMT202100432T1/it unknown
- 2016-09-15 HU HUE21170667A patent/HUE072064T2/hu unknown
- 2016-09-15 AU AU2016323447A patent/AU2016323447B2/en active Active
- 2016-09-15 BR BR112018004981-6A patent/BR112018004981A2/pt active Search and Examination
- 2016-09-15 ES ES21170667T patent/ES3030258T3/es active Active
- 2016-09-15 WO PCT/US2016/052014 patent/WO2017049011A1/en not_active Ceased
- 2016-09-15 ES ES16774748T patent/ES2881642T3/es active Active
- 2016-09-15 PT PT211706676T patent/PT3922645T/pt unknown
- 2016-09-15 LT LTEP21170667.6T patent/LT3922645T/lt unknown
- 2016-09-15 KR KR1020237037152A patent/KR102773636B1/ko active Active
- 2016-09-15 KR KR1020257005821A patent/KR20250033313A/ko active Pending
- 2016-09-15 DK DK21170667.6T patent/DK3922645T3/da active
- 2016-09-15 RS RS20250592A patent/RS66913B1/sr unknown
- 2016-09-15 SI SI201631904T patent/SI3922645T1/sl unknown
- 2016-09-15 CN CN202111206951.0A patent/CN113912718B/zh active Active
- 2016-09-15 PT PT167747484T patent/PT3350220T/pt unknown
- 2016-09-15 PL PL21170667.6T patent/PL3922645T3/pl unknown
- 2016-09-15 EP EP16774748.4A patent/EP3350220B1/en active Active
- 2016-09-15 CN CN202610263481.8A patent/CN122325604A/zh active Pending
- 2016-09-15 CN CN202111206864.5A patent/CN113896790B/zh active Active
- 2016-09-15 PL PL16774748T patent/PL3350220T3/pl unknown
- 2016-09-15 RS RS20210987A patent/RS62330B1/sr unknown
- 2016-09-15 EP EP24201758.0A patent/EP4461312A3/en active Pending
- 2016-09-15 CA CA3036652A patent/CA3036652A1/en active Pending
- 2016-09-15 HR HRP20211081TT patent/HRP20211081T1/hr unknown
- 2016-09-15 DK DK16774748.4T patent/DK3350220T3/da active
- 2016-09-15 HU HUE16774748A patent/HUE055331T2/hu unknown
-
2018
- 2018-03-14 CO CONC2018/0002703A patent/CO2018002703A2/es unknown
- 2018-03-14 MX MX2022005173A patent/MX2022005173A/es unknown
- 2018-03-14 MX MX2022005202A patent/MX2022005202A/es unknown
- 2018-03-14 MX MX2022005177A patent/MX2022005177A/es unknown
- 2018-03-14 MX MX2022005211A patent/MX2022005211A/es unknown
-
2020
- 2020-06-24 US US16/946,483 patent/US11439704B2/en active Active
-
2021
- 2021-08-10 CY CY20211100716T patent/CY1124619T1/el unknown
-
2022
- 2022-07-12 JP JP2022111605A patent/JP7418508B2/ja active Active
- 2022-07-21 US US17/814,221 patent/US12582712B2/en active Active
-
2023
- 2023-06-21 AU AU2023203922A patent/AU2023203922B2/en active Active
-
2024
- 2024-01-05 JP JP2024000878A patent/JP7785107B2/ja active Active
-
2025
- 2025-11-27 JP JP2025205441A patent/JP2026035721A/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003027248A2 (en) * | 2001-09-26 | 2003-04-03 | Wyeth | Antibody inhibitors of gdf-8 and uses thereof |
| WO2004037861A2 (en) * | 2002-10-22 | 2004-05-06 | Wyeth | Neutralizing antibodies against gdf-8 and uses therefor |
| WO2005066204A2 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| WO2006116269A2 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Inc. | Antibodies to myostatin |
| US20130209489A1 (en) * | 2010-08-16 | 2013-08-15 | Huiquan Han | Antibodies That Bind Myostatin, Compositions And Methods |
| WO2014182676A2 (en) * | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| WO2016073853A1 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016098357A1 (en) * | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| R. C. SMITH, M. S. CRAMER, P. J. MITCHELL, A. CAPEN, L. HUBER, R. WANG, L. MYERS, B. E. JONES, B. J. EASTWOOD, D. BALLARD, J. HANS: "Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH [, US, vol. 14, no. 7, 1 July 2015 (2015-07-01), US, pages 1661 - 1670, XP055328631, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-14-0681 * |
| ROSAMUND C. SMITH, BORIS K. LIN: "Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders", CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, vol. 7, no. 4, 1 November 2013 (2013-11-01), pages 352 - 360, XP055254846, ISSN: 1751-4258, DOI: 10.1097/SPC.0000000000000013 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12582712B2 (en) | Method of making anti-pro/latent myostatin antibodies | |
| US11925683B2 (en) | Compositions for making and using anti-Myostatin antibodies | |
| HK40117719A (en) | Anti-pro/latent-myostatin antibodies and uses thereof | |
| HK40064070B (en) | Anti-pro/latent-myostatin antibodies and uses thereof | |
| HK40064070A (en) | Anti-pro/latent-myostatin antibodies and uses thereof | |
| HK1258267B (en) | Anti-pro/latent-myostatin antibodies and uses thereof |